Recipient intramuscular administration of naked plasmid TGF-β1 attenuates lung graft reperfusion injury

Niccolò Daddi, Samer A. Kanaan, Takashi Suda, Tsutomu Tagawa, Franco D'Ovidio, Kathleen Grapperhaus, Benjamin D. Kozower, Jon H. Ritter, T. Mohanakumar, G. Alexander Patterson

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Background: Gene therapy may be an effective strategy for modulating lung graft ischemia-reperfusion injury. We investigated whether recipient intramuscular (IM) naked plasmid gene transfer of transforming growth factor β1-active (TGF-β1-active) ameliorates lung graft ischemia-reperfusion injury. Methods: Preliminary studies in F344 rats demonstrated that gastrocnemius muscle transfection of TGF-β1-active produced muscle and plasma protein expression at 24 and 48 hours after transfection. Recipients (n = 8) received IM injection of naked plasmid-encoding chloramphenicol acetyl transferase (CAT), TGF-β1-latent or TGF-β1-active, respectively, at 24 or at 48 hours before left lung transplantation. We did not treat the control group before transplantation (18-hour cold ischemia). Donor lungs were flushed with low-potassium dextran-1% glucose and stored for 18 hours at 4°C. All groups were killed at 24 hours after transplantation. Immediately before killing the animals, we clamped the contralateral right hilum and assessed graft function. We measured wet-to-dry ratio (W/D), myeloperoxidase, pro-inflammatory cytokines (interleukin 1 [IL-1], tumor necrosis factor α [TNF-α], interferon-γ [INF-γ], and IL-2) and performed immunohistochemistry. Results: Arterial oxygenation was greatest in the recipient group transfected with TGF-β1-active at 24 hours before transplantation compared with CAT, TGF-β1-latent, and 18-hour cold ischemia groups (p < 0.01). The W/D ratio and myeloperoxidase decreased in both 24- and 48-hour groups, with TGF-β1-active compared with CAT, and 18-hour cold ischemia groups (W/D, p < 0.02 and p < 0.004, respectively; myeloperoxidase, p < 0.05 and p < 0.01, respectively). All pro-inflammatory cytokines decreased in the 24-hour TGF-β1-active group compared with CAT, TGF-β1-latent, 18-hour and 1-hour cold ischemia, and non-treated lung groups (IL-1β, p < 0.03; TNF-α, p < 0.02; IFN-γ, p < 0.001; IL-2, p < 0.0001). In 24- and 48-hour groups with TGF-β1-active, immunohistochemistry showed marked staining of Type I and Type II alveolar cells and of macrophages from the apical to the caudal sections of the lung grafts. Conclusions: Recipient IM administration of naked plasmid encoding TGF-β1-active before transplantation ameliorates lung isograft reperfusion injury after prolonged ischemia.

Original languageEnglish
Pages (from-to)1323-1334
Number of pages12
JournalJournal of Heart and Lung Transplantation
Issue number12
Publication statusPublished - 12-2003
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation


Dive into the research topics of 'Recipient intramuscular administration of naked plasmid TGF-β1 attenuates lung graft reperfusion injury'. Together they form a unique fingerprint.

Cite this